Amide-Modified L-Dopa Derivatives for Stable Dopamine Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson’s Disease, primarily using levodopa, are ineffective in preventing disease progression and often result in side effects due to insolubility and rapid absorption, leading to fluctuating dopamine levels and premature death of dopaminergic neurons.
Innovation Solution
Development of stable L-dopa derivatives in a slow-release amide form that inhibit apoptotic pathways and provide a steady supply of dopamine, incorporating cysteine residues to scavenge ROS and inhibit inflammatory MAPK pathways, thereby protecting dopaminergic neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If L-dopa is used to treat Parkinson's disease, then dopamine levels are replenished, but the treatment does not prevent disease progression and causes side effects
Solution Approach 1:
The patent applies preliminary action by using L-dopa derivatives with amide groups that slowly release L-dopa over time, preventing the rapid absorption and subsequent oxidative stress that occurs with conventional L-dopa administration. This controlled, gradual release mechanism addresses the root cause of disease progression while maintaining dopamine replenishment.
Solution Approach 2:
The patent introduces an intermediary substance - the amide group - that modulates the release of L-dopa. This intermediary structure prevents direct, rapid conversion of L-dopa to dopamine, thereby reducing oxidative stress and preventing cell death while still achieving the therapeutic goal of dopamine replenishment.
2Quantity of substance
If large doses of L-dopa are used to maintain dopamine levels, then symptomatic relief is achieved, but insolubility and rapid absorption cause side effects and fluctuating dopamine levels
Solution Approach 1:
The amide-modified L-dopa derivatives are designed to undergo slow hydrolysis in the body, releasing L-dopa gradually. This preliminary structural modification prevents rapid absorption and the subsequent on/off fluctuations, providing stable dopamine levels without requiring large doses.
Solution Approach 2:
The patent changes the chemical parameter of L-dopa by introducing amide groups, which fundamentally alters its dissolution and release characteristics. This parameter change transforms the rapid, problematic absorption profile into a slow, controlled release pattern that maintains stable dopamine levels.
3Quantity of substance
If conventional L-dopa treatment is used, then dopamine is replenished, but oxidative stress and ROS production lead to premature death of dopaminergic neurons
Solution Approach 1:
The amide group serves as an intermediary that buffers the conversion of L-dopa to dopamine. This intermediate structure slows down the reaction, preventing the sudden oxidative stress and ROS production that occur with rapid L-dopa conversion, thereby protecting dopaminergic neurons from oxidative damage.
Solution Approach 2:
The patent applies preliminary action by pre-modifying L-dopa with amide groups before administration. This pre-modification ensures that when the drug is metabolized, L-dopa is released gradually, preventing the oxidative burst that would otherwise occur and protect neurons from oxidative stress.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The L-dopa derivatives offer improved bioavailability and stability, preventing neuronal cell death, maintaining consistent dopamine levels, and reducing oxidative stress, effectively addressing the limitations of existing treatments.
Implementation Method 1
The hydrolysis of the amide bond(s) is a rate limiting reaction that is responsible for a slow production of L-dopa and dopamine
Implementation Method 2
The oxidized environment at the dopaminergic cells leads to apoptosis and further deteriorations of the cells
Data Source
AI summary
The invention disclosed herein concerns a novel class of compounds suitable for the treatment of neurodegenerative diseases, such as Parkinson’s Disease.